Gastroenterology
Volume 132, Issue 2 , Pages 543-550 , February 2007

Identification of a Hepatitis B Virus S Gene Mutant in Lamivudine-Treated Patients Experiencing HBsAg Seroclearance

Received 15 January 2006 ,Accepted 15 November 2006.

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–496
  3. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–298
  4. Liaw YF, Lin DY, Chen TI, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9:235–241
  5. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–1956
  6. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (−)-2’,3’-dideoxy-3’-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992;267:22414–22420
  7. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2’,3’-dideoxy-3’-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991;88:8495–8499
  8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61–68
  9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–1661
  10. Chien RN, Liaw YF. Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology. 2003;46:362–366
  11. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, et al. Lamivudine therapy of WHV-infected woodchucks. Virology. 1998;245:18–32
  12. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997;71:9392–9399
  13. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172–180
  14. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393–399
  15. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996;24:714–717
  16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567–572
  17. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31:1318–1326
  18. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–693
  19. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336:325–329
  20. Wallace LA, Carman WF. Surface gene variation of HBV: scientific and medical relevance. Viral Hepatitis Rev. 1997;3:5–16
  21. Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamividine therapy for chronic hepatitis B virus infection. J Clin Microbiol. 2004;42:4882–4884
  22. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273
  23. Yeh CT, Shyu WC, Sheen IS, Chu CM, Liaw YF. Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: comparison with branched DNA assay. J Virol Methods. 1997;65:219–226
  24. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527
  25. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1989
  26. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005;32:102–112
  27. Gutierrez C, Devesa M, Loureiro CL, Leon G, Liprandi F, Pujol FH. Molecular and serological evaluation of surface antigen negative hepatitis B virus infection in blood donors from Venezuela. J Med Virol. 2004;73:200–207
  28. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005;42:480–485
  29. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, et al. Loss of the common “a” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 1992;90:2543–2547
  30. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet. 1995;345:1406–1407
  31. Kato J, Hasegawa K, Torii N, Yamauchi K, Hayashi N. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology. 1996;23:389–395
  32. Seddigh-Tonekaboni S, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A, et al. Effect of variation in the common “a” determinant on the antigenicity of hepatitis B surface antigen. J Med Virol. 2000;60:113–121
  33. Yeh CT, Chang MH, Lai HY, Chang ML, Chu CM, Liaw YF. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol. 2003;18:1129–1138
  34. Okamoto H, Imai M, Tsuda F, Tanake T, Miyakawa Y, Mayumi M. Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr. J Virol. 1987;61:3030–3034
  35. Hou J, Karayiannis P, Waters J, Luo K, Liang C, Thomas HC. A unique insertion in the S gene of surface antigen-negative hepatitis B virus Chinese carriers. Hepatology. 1995;21:273–278
  36. Tang JH, Yeh CT, Chen TC, Hsieh SY, Chu CM, Liaw YF. Emergence of an S gene mutant during thymosin α 1 therapy in a patient with chronic hepatitis B. J Infect Dis. 1998;178:866–869

 Supported by grants from Chang Gung Medical Research Program (CMRP34032 to the Hepatoma Research Team).

PII: S0016-5085(06)02559-5

doi: 10.1053/j.gastro.2006.12.001

Gastroenterology
Volume 132, Issue 2 , Pages 543-550 , February 2007

Article Tools

* Image Usage & Resolution